Fernández de Larrea Carlos, Delforge Michel, Davies Faith, Bladé Joan
Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Expert Rev Hematol. 2014 Feb;7(1):33-42. doi: 10.1586/17474086.2014.876899.
Monitoring multiple myeloma (MM) is essential during the evaluation of response to each therapy line, after transplantation and at the time of relapse or progression in all patients. An initial complete workup, including appropriate protein studies in serum and urine is mandatory. The use of uniform criteria is particularly important in the context of clinical trials. Complete remission (CR) definition, the goal for the majority of patients, is now in constant evolution, with immunophenotypic and molecular minimal residual disease measurement in bone marrow as well as imaging techniques. Identification of relapse/progression with traditional and novel techniques for eventual prompt intervention with rescue treatment is a current issue of debate.
在评估每位患者对各治疗线的反应期间、移植后以及复发或进展时，监测多发性骨髓瘤（MM）至关重要。必须进行初步的全面检查，包括血清和尿液中适当的蛋白质研究。在临床试验中，使用统一标准尤为重要。完全缓解（CR）的定义是大多数患者的目标，目前仍在不断演变，涉及骨髓中免疫表型和分子微小残留病的检测以及成像技术。使用传统和新技术识别复发/进展以便最终及时进行挽救治疗干预是当前一个有争议的问题。
